Immune system dendritic cells (DCs) are 'professional' antigen presenting cells (APCs) that are thought to play a critical role in the initiation of T lymphocyte-dependent immune responses (1) (2) (3) . DCs have also been reported to participate in the maintenance of immunological memory and the induction of immunological tolerance (4 -7). The precise lineage and functional characteristics of these cells, along with the related Langerhans cell, have been debated since their initial description (8, 9) . Recently, various subsets of DCs have been characterized. It is thought that different DC subsets may play distinct roles in different immunological responses (1, 2). As there is currently no single, widely accepted surface marker common to all human DCs, their identification depends on the demonstration of a characteristic morphology, the expression of a constellation of cell surface markers, and enhanced functional capacity (1) (2) (3) . This lack of a lineagespecific marker has complicated the study of human DCs because the number of cells required to fully evaluate the various cellular phenotypes recovered for functional experiments is often prohibitive.
Several methods for the isolation and/or generation of DCs have been described including conditions for generating the recently characterized 'immature' and 'mature' DC phenotypic subsets (1-3, 10 -15) . Tumor necrosis factor (TNF-␣) is one of several agents that have been reported to induce the phenotypic changes characteristic of mature DCs. The existing paradigm of dendritic cell action holds that the 'job' of immature resident dendritic cells is to continuously sample their surrounding tissue environment for antigens. In response to specific signals produced during inflammation, such as TNF-␣, the immature dendritic cells become activated and undergo an 'irreversible maturation' to a new phenotype. It has been proposed that this maturation event is required for DCs to acquire their full functional capacity and represents the terminal differentiation of this cell type (1-3, 12, 15-19) . This maturation process leads to a cessation of environmental sampling, the expression of new surface antigens, and migration of the mature dendritic cell to the lymph nodes where it can present its complement of 'sampled' antigens to T cells. After antigen presentation in the lymph node, it has been postulated that apoptotic death of the mature dendritic cell occurs and thus allows for down-regulation of the specific immune response (11, 15, 17, 19) . This model, however, does not easily accommodate a role for dendritic cells in immunological memory; it suggests limited potential for immunoregulation and appears to be biologically inefficient especially for rare cells with limited proliferative capacity. Therefore, we hypothesized that the process identified as 'maturation' might be a reversible phenomenon and would constitute an activation state rather than a state of terminal differentiation. Such a reversible capacity would be biologically more economic in that induction of immune responses by DCs would not be an obligatory one-time event. A transiently activated DC phenotype could also play a more global role in the regulation of subsequent immune processes, e.g., as in the recently described 'temporal bridge' between helper lymphocytes and cytotoxic effectors (20) . We generated large numbers of human dendritic cells from peripheral blood monocytes and extensively evaluated the functional and phenotypic effects of TNF-␣ in these preparations.
MATERIALS AND METHODS

Cellular preparations
Peripheral blood mononuclear cells (PBMC) were isolated from fresh normal donor apheresis packs by centrifugation over Ficoll (Pharmacia, Piscataway, N.J.) and elutriated (counterflow centrifugation) (J6M, Beckman, Palo Alto, Calif.), yielding populations of monocytes and lymphocytes which were Ͼ95% pure as demonstrated by FACS analysis. A portion of the elutriated monocytes and the lymphocytes were cryopreserved in the vapor phase of liquid nitrogen suspended in RPMI 1640 supplemented with 10% pooled human serum (BioWhittaker, Walkersville, Md.), L-glutamine (2 mM), HEPES (25 mM) (Gibco BRL Life Technologies, Gaithersburg, Md.), and 7.5% DMSO (Fisher Chemical, Fair Lawn, N.J.) for future use in functional testing and FACS analysis. Lymphocytes and monocytes were thawed immediately before use in all experimental analysis. Freshly isolated monocytes were cultured at 1 ϫ 10 6 cells/ml in RPMI 1640
(BioWhittaker) supplemented with L-glutamine (2 mM), sodium pyruvate (1 mM), nonessential amino acid mixture (1ϫ), penicillin (100 units/ml), streptomycin (100 g/ml) (Gibco BRL Life Technologies), 2-mercaptoethanol (50 M) (Sigma, St. Louis, Mo.), and 10% endotoxin free fetal calf serum (Atlanta Biologicals, Norcross, Ga.) at 37°C and 5% CO 2 . Granulocyte-macrophage colony stimulating factor (GM-CSF; 100 U/ml) and interleukin 4 (IL-4; 50 ng/ml, Ն 100 U/ml) were added at day 0. TNF-␣ (20 ng/ml, 200 U/ml) was added to aliquots of DC cultures at 10 -12 days (or as indicated) for 48 h to obtain activated DCs. H] thymidine (specific activity 5 Ci/mmol, Amersham Life Science, Arlington Heights, Ill.) on day 5 of culture. Cells were harvested using the Mach IIIm Harvester 96 (Tomtec Inc., Orange, Conn.) and specific activity was measured by liquid scintillation on the MicroBeta Trilux liquid scintillation counter (Wallac, Inc., Gaithersburg, Md.). The use of flat-bottom microplates results in somewhat lower proliferative responses, but better accommodates the large and more adherent TNF-␣-activated DCs.
Naive antigen immune responses
All cultures for the evaluation of naive antigen immune responses were performed in AIM V, serum-free media supplemented with sodium pyruvate (1 mM), nonessential amino acids (1ϫ) (Gibco BRL Life Technologies), and 2-mercaptoethanol (50 M; Sigma). APCs, either day 12 dendritic cells or autologous freshly thawed, cryopreserved monocytes, were incubated for 18 -24 h with 'endotoxin free KLH' (Calbio-chem, La Jolla, Calif.) at a concentration of 10 g/ml; the resulting endotoxin level of this lot was less than 0.04 EU (endotoxin unit) per milliliter. Activated DCs were exposed to TNF-␣ for 48 h prior to their addition to responding lymphocytes. All APCs were washed three times with PBS before addition to responding cells. Responding autologous lymphocytes were mixed with graduated numbers of keyhole limpet hemocyanin (KLH) pulsed, washed, stimulator dendritic cells or monocytes. Cells were cultured together for 10 days. These 'primed' T cells (1ϫ10 5 cells/well) were then restimulated with a second set of identically KLH pulsed, washed, irradiated, autologous APCs (either dendritic cells or cryopreserved monocytes from the same initial preparation) and cultured together. After 5 days of culture, cells were pulsed for 18 h with 3 H thymidine, harvested, and measured as described above.
Ribonuclease protection assays
Total RNA from DC preparations, cryopreserved monocytes, and cryopreserved lymphocytes was isolated using Trizol reagent (Life Technologies) according to the manufacturer's instructions. The Riboquant RPA kit and Multiprobe sets (PharMingen) were used according to the manufacturer's instructions with the exception that 32 P (Amersham Life Sciences) labeled probes were purified using TE Micro Select-D, G-25 microcentrifuge spin columns (5 Prime-3 Prime, Inc., Boulder, Colo.) to analyze 2-5 g of total RNA. Protected fragments were resolved on 6% polyacrylamide sequencing gels and quantitated on a BAS 1000 PhosphorImager (Fuji Medical Systems, Fairfield, N.J.). Signal strength was normalized to the GAPDH housekeeping gene message signal (essentially identical results were obtained if the L32 ribosomal RNA signal was used for normalization).
RESULTS
Morphological and phenotypic characterization of dendritic cells derived from peripheral blood monocytes.
We generated multiple preparations of Ͼ10 8 human DCs from single donors. In this report, DCs derived from peripheral blood monocytes in the presence of GM-CSF and IL-4 are defined as 'baseline DCs' (BL DCs) and those exposed to TNF-␣ as 'TNF-␣-activated DCs' (TNF-␣ DCs). The generation of BL DCs from monocytes was complete after 8 to 10 days, resulting in a morphologically and phenotypically uniform population of DCs with consistent yields of 10 to 25% relative to the initial cell number placed into culture. This yield was reproduced in more than 30 separate normal donor preparations. Monocyte preparations that demonstrated pronounced aggregation during elutriation resulted in very low yields of DC conversion; they were considered to be partially activated and were not used in subsequent studies. The DCs were routinely maintained in culture in excess of 28 days without significant cell loss while maintaining both their cell surface phenotype and functional capacity. Significant proliferation was not demonstrated as exemplified by background levels of 3 H thymidine incorporation over this period (data not shown). These BL DCs had the typical morphology (Fig. 1A) , with large irregular shapes and extensive cytoplasmic filopods and the pattern of cell surface marker expression reported for immature DCs (Fig. 2) . Notably, these cellular preparations did not express monocyte (CD14), lymphocyte (CD3 and CD19), natural killer cell (CD56), myeloid precursor (CD34), or mature DC (CD83) markers (21) . BL DCs differed further from autologous monocytes in having elevated cell surface molecule expression of MHC class I and MHC class II antigens, CD80, and low but detectable CD1a. The interpretation of possible attenuated expression of CD11a, CD11b, and CD33 was complicated by the significantly higher intrinsic autofluorescence of cultured DCs vs. autologous freshly thawed, cryopreserved monocytes. The addition of TNF-␣ to the culture media resulted within 48 h in an altered morphology (Fig. 1B) , with filopods being more coarse, more adherent, elongated, and with more extensive arborization. These changes were coincident with a shift in cell surface phenotype to that which has been reported for mature DCs (1-3, 10 -15, 17) , including enhanced expression of CD40, CD54, and CD80 and the induction of CD83 expression (Fig. 2) . Donordependent changes after exposure to TNF-␣ included variably attenuated expression of CD1a, CD11a, CD11b, CD32, and CD33, along with variable induction of CD86, whereas the remainder of the panel of cell surface molecules (CD1b, CD1c, CD11c, CD16, and CD95) were unchanged. The effects of TNF-␣ on cell surface phenotype were dose dependent within the concentration range of 0.05 ng/ml to 20 ng/ml (data not shown).
Characterization of allogeneic and naive antigen T cell responses elicited by BL DCs and TNF-␣ DCs.
Baseline and TNF-␣-activated DCs were evaluated for their immunostimulatory capacity in allogeneic mixed lymphocyte reactions (allo-MLRs) and for their ability to induce (prime) naive antigen responses. In allo-MLRs, both BL DCs and TNF-␣ DCs showed markedly enhanced stimulatory capacity relative to autologous freshly thawed, cryopreserved monocytes (Fig. 3A) . TNF-␣ DCs were two-to threefold more potent as stimulators than the BL DCs. We also evaluated our DC preparations for their capacity to prime an autologous, naive antigen immune response using endotoxin free KLH as the naive antigen (Fig. 3B) . Both baseline and TNF-␣-activated DCs primed naive antigen immune responses, albeit BL DCs less efficiently than TNF-␣ DCs, whereas To test the hypothesis that the effects of TNF-␣ may be reversible, we evaluated the cell surface molecule expression (Fig. 4) and functional capacity in alloMLRs (Fig. 5) of DCs transiently exposed to TNF-␣, followed by continued culture in the usual DC media without TNF-␣. Single donor BL DCs were divided at day 10, with one part of the preparation exposed to TNF-␣ for 48 h. We analyzed a portion of each of the resulting 12-day-old preparations, and both showed the expected cell surface phenotype and enhanced functional capacity (data not shown). The remainder of these baseline and TNF-␣-activated DC cultures were washed twice with PBS and placed into standard DC culture media without TNF-␣. Seven to 10 days after removal of the TNF-␣, there was no discernible difference in either the cell surface phenotype or the allo-MLR stimulatory capacity between the DCs previously exposed to TNF-␣ and autologous DCs maintained in the absence of TNF-␣. Re-exposure of the formerly activated DCs to TNF-␣ for 48 h again elicited the same activated cell surface phenotype (Fig. 4) and the enhanced immunostimulatory function (Fig. 5) . These phenotypic shifts were comparable to those seen in the control 19-day-old DCs, maintained in GM-CSF and IL-4 over the entire 'washout' period and exposed for the first time to TNF-␣ for 48 h. Thus, these effects of TNF-␣ are both reversible and reinducible.
Characterization of cytokine and chemokine expression profiles in the base line and TNF-␣-induced dendritic cell phenotypes.
To further characterize this TNF-␣-induced phenotype (activation state), we investigated the expression of cytokine mRNAs in BL DCs and TNF-␣ DCs using ribonuclease protection assays (RPA) (Fig. 6) . The mRNA levels for the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) and the cytokines IL-15, IL-12 p40, TNF-␣, LT-␣, and LT-␤ were all induced by 2-to 30-fold after 48 h of TNF-␣ exposure whereas IL-10, TGF-␤1, TGF-␤2, IL-1 RA, MIP-1␤, and MCP-1 mRNA levels were attenuated to levels 50% to 20% of 'baseline'. To evaluate the reversibility of the TNF-␣-induced modulation of cytokine expression patterns, we performed identical washout experiments to those described above. The results demonstrated a reversible and reinducible modulation of cytokine/chemokine expression that was entirely concordant with the functional and cell surface phenotypic changes (Fig. 6) .
DISCUSSION
Our results demonstrate that in human monocytederived dendritic cell preparations, the TNF-␣-induced cell surface phenotype and enhanced immunostimulatory capacity are both reversible and reinducible. Our baseline and TNF-␣-activated dendritic cells have the combination of morphological, phenotypic, and functional characteristics currently used to define human dendritic cells. BL DCs showed the typical morphology of immature DCs, did not express CD83, and modulated their cell surface phenotype and functional capacity when exposed to TNF-␣ in a manner consistent with that reported by others as being associated with maturation (1-3, 10 -15, 17). As previously described for immature DCs (13, 15) , these BL DCs were significantly more active in macropinocytosis than TNF-␣ DCs, (data not shown). The capacity of our BL DCs to prime for naive antigen responses does not in and of itself indicate a mature phenotype, particularly in light of the other immature characteristics seen in these preparations. The capacity of immature DCs to prime naive antigen responses has been controversial, with several groups reporting this capacity to be limited to mature DCs; recently, however, two groups have demonstrated the priming of naive antigen responses by both mature and immature DCs (10, 22) .
It is our interpretation that the transient effects of TNF-␣ constitute true reversion and not apoptotic cell death of mature DCs with repopulation from a pool of immature DCs. This conclusion is based on the maintenance of stable cell numbers over the course of these experiments, without demonstrable cell death or proliferation, and the demonstration that the preparations did not contain two discrete cell populations, mature (CD83ϩ) and immature (CD83-). Furthermore, it is unlikely that CD34ϩ cells could account for generation of the mature dendritic cells as all monocyte and DC preparations were negative for CD34ϩ cells by flow cytometry and did not undergo proliferation. Heterogeneous populations of cells containing DCs of the mature phenotype have been generated by the culture of CD34ϩ progenitor cells with various cytokines including the combination of GM-CSF and TNF-␣ both with and without IL-4 (23-26). The somewhat prolonged period required for reversion of the activated phenotype is not surprising given the paracrine induction of TNF-␣ message, the limited proliferative capacity of these cells, and their ability to be maintained in culture for at least a month without attenuation of any defining properties. Previous reports of irreversible TNF-␣-induced maturation in human DCs were based on detecting no change in phenotype in several days (27, 28) , 3 days (29) or at 2 to 3 days (22) . One of these groups (22) noted partial attenuation of the enhanced DC immunostimulatory capacity after culturing the DCs in the absence of TNF-␣ for 5 or 3 days, but they did not re-expose their DC preparations to TNF-␣. Notably, we observed only partial reversion of the cell surface phenotype 5 days after the 48 h pulse of TNF-␣ (data not shown). Thus, the apparent conflicting observations and interpretation of the effects of TNF-␣ on human DCs appear to be based on differences in experimental design.
In our DC preparations, the transient modulation of cytokine and chemokine mRNA expression by TNF-␣ may provide some insight into the potential immunoregulatory capacity of human DC subsets and lend further support to our suggestion that this mature phenotype represents an activation state. The cytokine mRNA expression pattern of DCs exposed to TNF-␣ as described in this and previous reports is in general agreement (30 -35) . However, previous reports did not directly evaluate modulation of cytokine mRNA expression associated with the maturation of DCs. The TNF-␣-induced cytokine mRNAs reported here are characteristic of proinflammatory immune mediators-IL-15, IL-12, LT-␣, LT-␤, TNF-␣, RANTES-whereas the attenuated mRNAs are generally representative of counter-regulatory or immunosuppressive cytokines: TGF-␤1, TGF-␤2, IL-1 RA, IL-10 (36, 37). Thus, exposure of human DCs to TNF-␣ results not only in the induction of proinflammatory mediators but also in the disengagement of a 'physiological brake' on the immune response by down-regulation of counterregulatory cytokines. This reversible pattern of cytokine expression suggests that the accentuated immunostimulatory capacity seen with TNF-␣-activated DCs may be due to the modulation of immunoregulatory cytokines as well as induction of cell surface accessory/costimulatory molecules. The gradual in vitro reversion to a 'baseline' state, which includes reinduction of counter-regulatory immune mediators, may be necessary and critical to appropriate regulation of the in vivo immune response, thereby providing an alternative mechanism to apoptosis of mature DCs for avoiding persistent, dysregulated stimulation of the immune response.
Our data suggest that the selection of dendritic cell preparations for use in eliciting any particular in vivo or in vitro immunomodulation may be critical. The expression of IL-10 and other counter-regulatory immune mediators by BL DCs would suggest Allo-MLRs performed with a portion of these cultures at day 12, with the first exposure to TNF-␣, gave results nearly identical to DC 'A' and DC 'B'. The error bars represent standard deviation of the mean for five replicate wells. All responding allogeneic lymphocytes were isolated from the same donor. The following controls had 3 H thymidine incorporation, including Ϯ sd, Ͻ1000 CPM at all dilutions, and are therefore not depicted: responding lymphocytes alone and APCs alone (monocytes, baseline DCs, and TNF-␣-activated DCs). The data are representative of three separate washout experiments, all of which yielded similar results. Cell surface phenotype for these preparations are represented in Fig. 4 by rows C, D, E, and F, respectively. that preparations like these would be of benefit for purposes of attenuating autoimmune phenomena (38) or providing a Th2/humoral immune response, but less likely to produce benefit where a robust, Th1-biased immune response is desired such as in anti-tumor immunotherapies (7, 39) . Furthermore, the ability of other cytokine combinations to substitute for TNF-␣ in the generation of DCs from CD34ϩ progenitors and in the induction of the mature DC phenotype suggests that other immune mediators will be able to directly activate DCs, although not necessarily with identical modulation of cytokine expression.
Based on the observations detailed here, the existing model of dendritic cell functional development can be expanded to include the capacity to cycle between DC effector phenotypes, Fig. 7 . Dendritic cells have been shown to undergo cell death or reversion to macrophage morphology (28, 29, 40) upon withdrawal of all cytokine support. Recently it was demonstrated that persistent stimulation with GM-CSF can sustain immature DCs upon removal of IL-4 (41). The current view that, in vivo, mature (activated) DCs undergo apoptotic cell death after migration to lymphoid tissues has not been demonstrated directly and is based in part on the relative absence of DCs in efferent lymph of antigen primed animals (42) (43) (44) (45) . Thus, the presence or absence of various trophic factors (46) and immune mediators may well determine the ultimate fate of activated (mature) DCs within lymphoid tissues. This could range from apoptosis, which might occur in the presence of continuous or overwhelming activating stimuli (circumventing a failure to reinduce counterregulatory cytokines), to quiescent or 'memory' states, or even return to the periphery as reverted BL DCs with resumption of antigenic surveillance. Our data suggest that for human dendritic cells there is a dynamic balance between antigen capture, processing, presentation, and immunostimulatory capacity that can shift in response to the immune mediators, such as TNF-␣, present in the microenvironment.
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